These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35847747)

  • 1. Use of daratumumab in high risk multiple myeloma: A meta-analysis.
    Premkumar V; Pan S; Lentzsch S; Bhutani D
    EJHaem; 2020 Jul; 1(1):267-271. PubMed ID: 35847747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
    Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
    Front Oncol; 2020; 10():624661. PubMed ID: 33680948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.
    Giri S; Grimshaw A; Bal S; Godby K; Kharel P; Djulbegovic B; Dimopoulos MA; Facon T; Usmani SZ; Mateos MV; Costa LJ
    JAMA Oncol; 2020 Nov; 6(11):1759-1765. PubMed ID: 32970151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations.
    Arnall JR; Maples KT; Harvey RD; Moore DC
    Ann Pharmacother; 2022 Aug; 56(8):927-940. PubMed ID: 34963325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high-risk cytogenetics: A meta-analysis of randomized controlled trials.
    Chakraborty R; Siddiqi R; Willson G; Gupta S; Asghar N; Husnain M; Aljama MA; Behera TR; Anwer F; Perrot A; Riaz IB
    Cancer; 2022 Jun; 128(12):2288-2297. PubMed ID: 35377484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy.
    Dima D; Dower J; Comenzo RL; Varga C
    Cancer Manag Res; 2020; 12():7891-7903. PubMed ID: 32904669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab: A review of current indications and future directions.
    Hill E; Morrison C; Kazandjian D
    Semin Oncol; 2022 Feb; 49(1):48-59. PubMed ID: 35184871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.
    Kaufman JL; Dimopoulos MA; White D; Benboubker L; Cook G; Leiba M; Morton J; Joy Ho P; Kim K; Takezako N; Moreau P; Sutherland HJ; Magen H; Iida S; Kim JS; Miles Prince H; Cochrane T; Oriol A; Bahlis NJ; Chari A; O'Rourke L; Trivedi S; Casneuf T; Krevvata M; Ukropec J; Kobos R; Avet-Loiseau H; Usmani SZ; San-Miguel J
    Blood Cancer J; 2020 Nov; 10(11):111. PubMed ID: 33149130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.
    Markovic U; Romano A; Del Fabro V; Bellofiore C; Bulla A; Parisi MS; Leotta S; Gentile M; Cangialosi C; Vincelli I; Mineo G; Rossi M; Poidomani M; Uccello G; Maugeri C; Mannina D; Innao V; Di Raimondo F; Conticello C
    Front Oncol; 2021; 11():624405. PubMed ID: 33763359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
    Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review.
    Tauseef A; Zafar M; Silberstein P; Nahas J; Frederickson T; Abodunrin F; Abbas A; Arshad W; Lateef N; Rangoonwala H; Albagoush S; Mirza M
    J Family Med Prim Care; 2022 Jun; 11(6):2648-2655. PubMed ID: 36119264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.
    Sanchez L; Richter J; Cho HJ; Jagannath S; Madduri D; Parekh S; Richard S; Tam L; Verina D; Chari A
    Ther Adv Hematol; 2021; 12():2040620720987075. PubMed ID: 33613930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.
    Weisel K; Spencer A; Lentzsch S; Avet-Loiseau H; Mark TM; Spicka I; Masszi T; Lauri B; Levin MD; Bosi A; Hungria V; Cavo M; Lee JJ; Nooka A; Quach H; Munder M; Lee C; Barreto W; Corradini P; Min CK; Chanan-Khan AA; Horvath N; Capra M; Beksac M; Ovilla R; Jo JC; Shin HJ; Sonneveld P; Casneuf T; DeAngelis N; Amin H; Ukropec J; Kobos R; Mateos MV
    J Hematol Oncol; 2020 Aug; 13(1):115. PubMed ID: 32819447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
    Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Anderson LD; Bal S; Dhakal B; Nathwani N; Shah N; Medvedova E; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Schmidt T; Orlowski RZ; Shain KH; Cowan AJ; Dholaria B; Cornell RF; Jerkins JH; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG; Voorhees PM
    Transplant Cell Ther; 2023 Mar; 29(3):174.e1-174.e10. PubMed ID: 36494017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
    Avet-Loiseau H; San-Miguel J; Casneuf T; Iida S; Lonial S; Usmani SZ; Spencer A; Moreau P; Plesner T; Weisel K; Ukropec J; Chiu C; Trivedi S; Amin H; Krevvata M; Ramaswami P; Qin X; Qi M; Sun S; Qi M; Kobos R; Bahlis NJ
    J Clin Oncol; 2021 Apr; 39(10):1139-1149. PubMed ID: 33513030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
    Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
    Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.
    Mateos MV; Spencer A; Nooka AK; Pour L; Weisel K; Cavo M; Laubach JP; Cook G; Iida S; Benboubker L; Usmani SZ; Yoon SS; Bahlis NJ; Chiu C; Ukropec J; Schecter JM; Qin X; O'Rourke L; Dimopoulos MA
    Haematologica; 2020; 105(2):468-477. PubMed ID: 31221782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis.
    Xu W; Li D; Sun Y; Ran X; Wang B; Wu W; Sheng Z; Liu L
    Eur J Haematol; 2019 Dec; 103(6):542-551. PubMed ID: 31444819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials.
    Htut TW; Thein KZ; Lawrie A; Tighe J; Preston G
    EJHaem; 2020 Jul; 1(1):262-266. PubMed ID: 35847725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
    Plesner T; van de Donk N; Richardson PG
    Cells; 2020 Feb; 9(2):. PubMed ID: 32041300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.